DCAT Value Chain Insights

Profits and Pharma: The Impact of COVID-19

Reflecting the fallout from the COVID-19 pandemic, real GDP in the US decreased at an annual rate of 32.9% in the second quarter, and GDP in the eurozone shrank by 12.1%, both historical lows. How...

Novel Excipients: Gaining Traction in the Industry

The FDA is considering a pilot program for the toxicological and quality evaluation of novel excipients. Excipients now are not separately reviewed by the FDA, and some say a separate review...

SPONSORED CONTENT

A Cambrex Webinar - Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Information
June 8, 2020
Sponsored by Cambrex

Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh, discusses the importance of understanding crystallization processes to avoid unnecessary cost, risk and development delays.

Read More
Overcoming Challenges to Deliver Fixed Dose Combination (FDC) Drug Products

Information
June 2, 2020
Sponsored by Cambrex

With Cambrex’s experience in combining two or more active pharmaceutical ingredients (APIs) into Fixed Dose Combination drugs (FDCs), we are the CDMO that’s expertly positioned to partner with you...

Read More
Q&A with Stephan Haitz, President, CDMO Sales & Marketing at Cambrex

Information
March 9, 2020
Sponsored by Cambrex

Stephan Haitz, President, CDMO Sales & Marketing discusses small molecule trends and how the CDMO industry is constantly evolving to meet the demands and needs of the growing clinical pipeline.

Read More